ObsEva SA (OBSV) Coverage Initiated at Royal Bank Of Canada
Stock analysts at Royal Bank Of Canada started coverage on shares of ObsEva SA (NASDAQ:OBSV) in a research note issued on Thursday. The brokerage set an “outperform” rating and a $22.00 price target on the stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 216.55% from the stock’s previous close.
OBSV has been the topic of several other research reports. Zacks Investment Research lowered shares of ObsEva SA from a “hold” rating to a “sell” rating in a report on Saturday, August 19th. HC Wainwright initiated coverage on shares of ObsEva SA in a report on Thursday, June 29th. They set a “buy” rating and a $27.00 target price on the stock. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $18.00 target price on shares of ObsEva SA in a report on Wednesday, August 16th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. ObsEva SA currently has an average rating of “Buy” and a consensus price target of $23.00.
ObsEva SA (OBSV) opened at 6.95 on Thursday. The firm’s market cap is $198.05 million. ObsEva SA has a one year low of $6.77 and a one year high of $14.18. The stock’s 50 day moving average is $6.96 and its 200-day moving average is $9.67.
ObsEva SA (NASDAQ:OBSV) last released its earnings results on Tuesday, August 15th. The company reported ($0.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.13). During the same quarter in the prior year, the company earned ($0.30) EPS. On average, equities research analysts expect that ObsEva SA will post ($2.38) earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Baker Avenue Asset Management LP purchased a new stake in ObsEva SA during the 1st quarter valued at $104,000. Paloma Partners Management Co purchased a new stake in ObsEva SA during the 1st quarter valued at $131,000. Sphera Funds Management LTD. boosted its position in ObsEva SA by 9.7% during the 2nd quarter. Sphera Funds Management LTD. now owns 231,497 shares of the company’s stock valued at $1,979,000 after buying an additional 20,411 shares during the period. Iguana Healthcare Management LLC purchased a new stake in ObsEva SA during the 1st quarter valued at $260,000. Finally, Spark Investment Management LLC purchased a new stake in ObsEva SA during the 1st quarter valued at $518,000. 48.46% of the stock is owned by institutional investors and hedge funds.
About ObsEva SA
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.